ADC Ther­a­peu­tics sells off roy­al­ty share for lead an­ti­body-drug con­ju­gate in $325M deal

ADC Ther­a­peu­tics will re­ceive $225 mil­lion in cash and an ad­di­tion­al $100 mil­lion in near-term mile­stones as part of a roy­al­ty sale with Health­Care Roy­al­ty for its lead an­ti­body-drug con­ju­gate Zyn­lon­ta and in­ves­ti­ga­tion­al CD25 can­di­date cami­dan­lum­ab tesirine (Ca­mi), the com­pa­nies said Thurs­day.

The deal snares Health­Care Roy­al­ty a 7% roy­al­ty on world­wide net sales and li­cens­ing for both drugs, which can be ex­pand­ed up to 10%. The deal ends when the $325 mil­lion has been re­couped be­tween 2.25x and 2.5x, ADC said.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER